by Rhoda Wilson, All News Pipeline:

Pfizer’s vaccine for RSV is another among hundreds of novel biotechnology vaccines currently under development for a range of diseases that have gained approval from the US Food and Drug Administration.

RSV of a common respiratory illness that usually causes mild cold-like symptoms, yet the vaccine industry wants to portray that the benefits of its experimental vaccines outweigh the risks. While medical institutions seem determined to support pharmaceutical interventions that not only don’t work but also harm recipients.